碟脉灵注射液治疗急性脑梗死疗效观察

为了观察碟脉灵注射液治疗急性脑梗死的疗效及安全性,采用随机、对照、开放试验,将110例急性脑梗死患者分为低分子肝素钙组(n=34)、碟脉灵注射液组(n=36)和低分子肝素钙加碟脉灵注射液组(n=40),观察治疗前后的神经功能缺损评分、疗效、血浆纤维蛋白原含量、肝肾功能、血常规及心电图,头颅计算机断层成像测定脑梗死最大面积、。结果发现,治疗14天、28天时,低分子肝素钙组和碟脉灵注射液组神经功能缺损评分降低接近(P>0.05),低分子肝素钙加碟脉灵注射液组神经功能缺损评分比低分子肝素钙组和碟脉灵注射液组降低更明显(P<0.05和P<0.01)。治疗14天,低分子肝素钙组、碟脉灵注射液组和低分子肝素钙加碟脉灵注射液组总有效率分别为50％、52.7％和67.5％;治疗28天分别为70.6％、72％和87.5％。低分子肝素钙加碟脉灵注射液组疗效优于低分子肝素钙组和碟脉灵注射液组(P<0.01),而低分子肝素钙组与碟脉灵注射液组疗效无显著性差异。低分子肝素钙加碟脉灵注射液组基本痊愈率、显著进步率均高于低分子肝素钙治疗组和碟脉灵注射液治疗组。碟脉灵注射液组和低分子肝素钙加碟脉灵注射液组缺血性心电图的改善优于低分子肝素钙组(P<0.01)。治疗前后三组纤维蛋白原和最大梗死面积无明显改变。用药过程中,患者耐受性好,未发现

Therapeutic Effects on Acute Cerebral Infarction Treated by Die-Mai-Ling Injection

Aim To observe therapeutic effects and safety of Die-mai-ling injection (DMLI) on acute cerebral infarction. Methods 110 cases with acute cerebral infarction were randomly divided into three groups. 34 cases were given low molecular heparin (LMWH), 36 cases were given DMLI, and 40 cases were given DMLI + LMWH. Supporting treatment and heteropathy were employed in three groups. Neurological scales, therapeutic assessment, fibroprotein and the largest infarction area in CT of this attack were compared in three groups before and after treatment. Liver and renal function, blood routine and ECG were observed simultaneously. Results On the 14 th and 28 th day after treatment, neurological scales decreased significantly in the LMWH + DMLI group compared with LMWH group and DMLI group ( P < 0.05 or P < 0.01), there was no significant difference between LMWH group and DMLI group ( P > 0.05). On the 14th and 28 th day, the total effective rate of LMWH group, DMLI group and LMWH + DMLI group was 50% , 52.7%, 67.5% and 70.6% , 72% , 87.5%, LMWH+DMLI group was significantly higher than LMWH group and DMLI group ( P < 0.01), but no significant difference was found between LMWH group and DMLI group (P > 0.05). Rates of healing in LMWH + DMLI group was higher than LMWH group and DMLI group. The recovery ratio of DMLI group and LMWH + DMLI group was higer than that of LMWH group ( P < 0.01). There was no significant difference on the fibroprotein levels and the largest infarction area in the three groups before and after treatment ( P > 0.05). The treatment of DMLI was well toloranced, no adverse effects on liver and renal function and blood routine were observed. Conclusions DMLI is effective for the treatment of acute cerebral infarction, which curative effect is similar to LMWH. DMLI conjoined with LMWH in the treatment of acute cerebral infarction can improve effective rates significantly. The safety and tolerance of DMLI were comparatively good.